ABBV241213P145000
- 0.11
- 0.000.00%
AbbVie Newsroom
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Press Release: AbbVie Completes Acquisition of Aliada Therapeutics
AbbVie Completes Acquisition Of Aliada Therapeutics >ABBV
BofA Securities Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $191
AbbVie Completes Acquisition of Aliada Therapeutics
AbbVie (ABBV.US) JAK inhibitor "upadacitinib" is proposed for priority review in China.
On December 10, the official website of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration announced that AbbVie (ABBV.US) has applied for the inclusion of upadacitinib sustained-release tablets in priority review, with the intended indication being the treatment of adult giant cell arteritis (GCA).
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
AbbVie Treatment of Multiple Myeloma Granted FDA Orphan Designation
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Analyst Scoreboard: 19 Ratings For AbbVie
B of A Securities Reinstates Neutral on AbbVie, Announces $191 Price Target
AbbVie Analyst Ratings
Citi Maintains AbbVie(ABBV.US) With Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)
TD Cowen Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $225
AbbVie: Strong Buy Rating Based on Growth Potential and Strategic Positioning
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
AbbVie's Phase III Trial of Parkinson's Disease Treatment Meets Primary Endpoint
AbbVie (ABBV.US) has reached the key endpoint in the phase 3 trial of the investigational small molecule therapy tavapadon, with plans to submit a marketing application in 2025.
The complete results of the trial will be announced at future medical conferences, and AbbVie expects to submit a New Drug Application (NDA) for the drug to the usa FDA in 2025.